MARKETS
Markets

Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study

Aug 10, 2026 · 02:06 PM ET· updated 1h ago
Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study

Aquestive Therapeutics reports positive study results for Anaphylm sublingual film, paving the way for a Q3 FDA resubmission.

Share
Why It Matters

Aquestive's allergy medicine passed an important test, so they're sending it back to the FDA (the government group that approves medicines) to try again. When a company gets good test results and resubmits, it shows they're making progress, though the FDA still has to say yes.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.